25 Participants Needed

Cold Preservation vs. Machine Perfusion for Liver Transplants

JS
MC
KM
AR
HK
Overseen ByHeather Kuenz, RN, BSN
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Washington University School of Medicine
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the treatment Declined liver in Normothermic Machine Perfusion (NMP) for liver transplants?

Research shows that using normothermic machine perfusion (NMP), which keeps the liver at body temperature, can be more effective than traditional cold storage methods. Studies suggest that NMP may reduce damage to the liver and improve outcomes after transplantation.12345

Is normothermic machine perfusion (NMP) safe for liver transplants?

Normothermic machine perfusion (NMP) for liver transplants has been shown to be safe in clinical trials, with improved liver function compared to traditional cold storage methods. However, there are potential technical risks, and more extensive studies are needed to fully understand its safety profile.15678

How does the treatment of declined liver in normothermic machine perfusion differ from other treatments for liver transplants?

Normothermic machine perfusion (NMP) is unique because it preserves donor livers at body temperature, allowing for better evaluation and potentially improved liver function compared to the traditional method of static cold storage (SCS), which keeps the liver at low temperatures.12579

What is the purpose of this trial?

This is a prospective, non-randomized, clinical trial of discarded liver transplants that have received normothermic machine perfusion (NMP), compared with standard cold preservation liver transplants. The discarded livers rejected by all other centers and meeting pre-NMP eligibility criteria will receive NMP using the OrganOx® metra device. The NMP-treated liver that meets the viability criteria will be transplanted to patients who are eligible and consented to the study. Liver transplant outcomes will be ascertained during 12 months post-transplantation. The results of the trial will be compared with those of contemporary comparison groups of patients who received the standard criteria donor liver transplantation.

Research Team

WC

Will Chapman, M.D.

Principal Investigator

Washington University School of Medicine

Eligibility Criteria

This trial is for adults with end-stage liver disease who are on the UNOS waiting list for a primary liver transplant. They must be able to walk over 350 meters in six minutes or have mild/no frailty. Donors' livers, which were declined by other centers and meet specific criteria including weight and ischemia times, will be used.

Inclusion Criteria

My organ was not properly flushed during surgery.
I am considered not frail or mildly frail according to a recent test, or I can walk more than 350 meters in 6 minutes.
'Rapid Recovery' donors for liver procurement, meeting the above criteria
See 6 more

Exclusion Criteria

Subject MELD score 29 or higher
Donor serum bilirubin greater than or equal to 5 mg/dL
I am receiving a second liver transplant.
See 12 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Transplantation of NMP-treated livers to eligible patients

Immediate
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after transplantation

6 months
Regular visits (in-person)

Extended Follow-up

Long-term monitoring of liver graft function and patient survival

12 months

Treatment Details

Interventions

  • Declined liver in Normothermic Machine Perfusion (NMP)
  • Standard cold preservation of liver
Trial Overview The study compares outcomes of liver transplants using two preservation methods: standard cold storage versus Normothermic Machine Perfusion (NMP) with the OrganOx® metra device on previously discarded livers. The effectiveness of NMP-treated livers that pass viability tests will be evaluated over a year.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Declined liver in Normothermic Machine Perfusion (NMP)Experimental Treatment1 Intervention
The discarded livers rejected by all other centers and meeting pre-NMP eligibility criteria will receive NMP using the OrganOx® metra device. The NMP-treated liver that meets the viability criteria will be transplanted to patients who are eligible and consented to the study. NMP of the donated declined liver utilizing the OrganOx® metra device. NMP involves (warm) machine perfusion with oxygenated blood at normal body temperature. During NMP, the device also allows for ongoing assessment of donor liver function and further viability assessment to help determine suitability of the organ for transplant.
Group II: Standard cold preservation of liverActive Control1 Intervention
This group will receive liver transplant using the standard method of preservation. There will be 3 comparison groups: one local comparison group and two comparison groups from the national UNOS data.

Declined liver in Normothermic Machine Perfusion (NMP) is already approved in United States, European Union for the following indications:

🇺🇸
Approved in United States as Normothermic Machine Perfusion for:
  • Liver transplantation for end-stage liver disease
🇪🇺
Approved in European Union as Normothermic Machine Perfusion for:
  • Liver transplantation for end-stage liver disease

Find a Clinic Near You

Who Is Running the Clinical Trial?

Washington University School of Medicine

Lead Sponsor

Trials
2,027
Recruited
2,353,000+

OrganOx Ltd.

Industry Sponsor

Trials
4
Recruited
630+

Mid-America Transplant

Collaborator

Trials
6
Recruited
1,700+

Findings from Research

In a study involving 383 donor livers from 15 US transplant centers, normothermic machine perfusion (NMP) did not significantly reduce early allograft dysfunction (EAD) compared to static cold storage (SCS), with rates of 20.6% for NMP and 23.7% for SCS.
However, NMP showed a notable benefit for higher-risk donor livers, particularly those from donors after circulatory death, where EAD rates were significantly lower (22.8% for NMP vs 44.6% for SCS), and it also reduced the incidence of postreperfusion syndrome (5.9% vs 14.6%).
Normothermic Machine Perfusion of Donor Livers for Transplantation in the United States: A Randomized Controlled Trial.Chapman, WC., Barbas, AS., D'Alessandro, AM., et al.[2023]
Normothermic machine perfusion (NMP) significantly prolonged liver preservation time (21 hours) compared to static cold storage (SCS) (7 hours) without negatively impacting patient or graft survival rates after one year, which were similar between the two methods.
NMP was associated with a significantly lower incidence of ischaemic-type bile duct lesions (3% in NMP vs. 14% in SCS), suggesting that NMP may offer a safer preservation method for liver transplants.
Static cold storage compared with normothermic machine perfusion of the liver and effect on ischaemic-type biliary lesions after transplantation: a propensity score-matched study.Fodor, M., Cardini, B., Peter, W., et al.[2022]
Hypothermic oxygenated machine perfusion (HOPE/D-HOPE) significantly improves graft and patient survival rates compared to static cold storage (SCS), with a hazard ratio of 0.40, indicating a 60% reduction in risk of graft failure.
HOPE also reduces the incidence of biliary complications compared to SCS, suggesting it is a safer option for preserving donor livers, while normothermic machine perfusion (NMP) did not show significant advantages over SCS.
A Meta-Analysis and Systematic Review of Normothermic and Hypothermic Machine Perfusion in Liver Transplantation.Mugaanyi, J., Dai, L., Lu, C., et al.[2023]

References

Normothermic Machine Perfusion of Donor Livers for Transplantation in the United States: A Randomized Controlled Trial. [2023]
Static cold storage compared with normothermic machine perfusion of the liver and effect on ischaemic-type biliary lesions after transplantation: a propensity score-matched study. [2022]
A Meta-Analysis and Systematic Review of Normothermic and Hypothermic Machine Perfusion in Liver Transplantation. [2023]
Liver Transplantation Outcomes From Controlled Circulatory Death Donors: SCS vs in situ NRP vs ex situ NMP. [2023]
Cold storage or normothermic perfusion for liver transplantation: probable application and indications. [2022]
Clinical Implementation of Prolonged Liver Preservation and Monitoring Through Normothermic Machine Perfusion in Liver Transplantation. [2021]
Preliminary Single-Center Canadian Experience of Human Normothermic Ex Vivo Liver Perfusion: Results of a Clinical Trial. [2023]
The Role of Normothermic Perfusion in Liver Transplantation (TRaNsIT Study): A Systematic Review of Preliminary Studies. [2023]
Preliminary Experience With Hypothermic Oxygenated Machine Perfusion in an Italian Liver Transplant Center. [2019]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security